Company Dossier · Health Care
Align Technology
- S&P 500
- Russell 1000
What Align Technology is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $4.14 billion, up 4.5% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.63 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.12 billion, up 20% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.47 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 29, 2026): sentiment 0.10 on a −1 to +1 scale (mixed), confidence 0.70 of 1.Palanor Discourse
- Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 4 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 27, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q1 2026: $1.5 million on the open market.SEC Form 4
- 678 institutional managers reported a position at June 30, 2026 (−15 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 33 (40 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Align Technology is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Hedging
Expanding ↔ Retrenching
Steady
- Capital spending89th pct
- Debt raised—
- Buybacks vs capex73rd pct
- Hiring filings58th pct
- Deals and private raises49th pct
- Patent publications18th pct
Confident ↔ Hedging
Hedging
- Call sentiment22nd pct
- Call confidence53rd pct
- Guidance changes63rd pct
- Risk factors added19th pct
- Insider open-market trades—
- − Call sentiment
- − Risk factors added
- + Guidance changes
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver93rd pct
- Stress filings48th pct
Credit
How these are built →No bond term sheets or tagged debt on file for Align Technology yet.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Oct 13, 2026Patent
- Sep 3, 2026Trademark
- Aug 31, 20268-KDirector or officer changeItem 5.02
- Jul 9, 20268-KDirector or officer changeItem 5.02
- Jul 2, 2026Trademark
- Jun 22, 20268-KDirector or officer changeItem 5.02
- Jun 22, 2026Trademark
- Jun 22, 2026Trademark
- Jun 22, 2026Trademark
- May 20, 20268-KShareholder vote resultsItem 5.07
- Feb 27, 202610-KAnnual report (10-K)3 risk factors added, 0 removed
- Sep 18, 20258-KDirector or officer changeItem 5.02
- Jul 2, 20258-KDirector or officer changeItem 5.02
- May 21, 20258-KShareholder vote resultsItem 5.07
- May 21, 20258-KDirector or officer changeItem 5.02
- Feb 28, 202510-KAnnual report (10-K)1 risk factors added, 1 removed
- Feb 28, 202410-KAnnual report (10-K)1 risk factors added, 2 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Cooper Companies (The) COO | $4.2B | $0.7B | Jul 31, 2026 |
| West Pharmaceutical Services WST | $3.3B | $0.4B | Jun 30, 2026 |
| Envista NVST | $2.9B | $0.3B | Jul 3, 2026 |
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |
| Charles River Laboratories CRL | $4.0B | $0.4B | Jun 27, 2026 |
| Illumina, Inc. ILMN | $4.5B | $0.9B | Jun 28, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Jazz Pharmaceuticals JAZZ | $4.6B | $1.6B | Jun 30, 2026 |